New UK ADR research centre set up
This article was originally published in Scrip
Executive Summary
Four pharmaceutical companies and the UK Medical Research Councilare among the financial supporters of a new centre aimed at reducing the risks of adverse drug effects. The MRC Centre for Drug Safety Science will be based at the University of Liverpool's school of biomedical sciences and will provide training programmes for clinical and non-clinical drug safety scientists. It will be led by director Professor Kevin Park and will also involve researchers at Manchester University. The centre has received £3.7 million in funding from the MRC, and companies supporting the centre includeAstraZeneca, Novartis, PfizerandMerck & Co.
You may also be interested in...
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.
Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.